178 related articles for article (PubMed ID: 16236618)
1. Transformation of MALT lymphoma to pure plasma cell histology following treatment with the anti-CD20 antibody rituximab.
Woehrer S; Streubel B; Chott A; Hoffmann M; Raderer M
Leuk Lymphoma; 2005 Nov; 46(11):1645-9. PubMed ID: 16236618
[TBL] [Abstract][Full Text] [Related]
2. Plasmacytic differentiation in MALT lymphomas following treatment with rituximab.
Troch M; Kiesewetter B; Dolak W; Jaeger U; Püspök A; Müllauer L; Chott A; Raderer M
Ann Hematol; 2012 May; 91(5):723-728. PubMed ID: 22186828
[TBL] [Abstract][Full Text] [Related]
3. Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma.
Raderer M; Jäger G; Brugger S; Püspök A; Fiebiger W; Drach J; Wotherspoon A; Chott A
Oncology; 2003; 65(4):306-10. PubMed ID: 14707449
[TBL] [Abstract][Full Text] [Related]
4. Treatment of localized oral MALT lymphoma by rituximab: a case report.
Yamagata K; Onizawa K; Kojima H; Yoshida H
Oral Maxillofac Surg; 2008 Dec; 12(4):227-30. PubMed ID: 18830723
[TBL] [Abstract][Full Text] [Related]
5. Rituximab-induced remission of a gastric MALT lymphoma.
Datta YH; Kampalath B; Binion DG
Leuk Lymphoma; 2004 Jun; 45(6):1297-9. PubMed ID: 15360017
[TBL] [Abstract][Full Text] [Related]
6. Transformation of MALT lymphoma to pure plasma cell histology: possible association with anti-CD20 antibody treatment.
Klein N; Elis A; Radnay J; Zemer R; Klein A; Lishner M
Isr Med Assoc J; 2009 Nov; 11(11):703-4. PubMed ID: 20108563
[No Abstract] [Full Text] [Related]
7. Primary breast mucosa-associated lymphoid tissue (MALT) lymphoma with high-grade transformation evidenced by prominent lymphoepithelial lesions.
Taeda Y; Ariga N; Okamura K; Takei N; Komeno T; Ueki H; Ohtani H
Breast Cancer; 2006; 13(3):322-327. PubMed ID: 16929129
[TBL] [Abstract][Full Text] [Related]
8. Increased plasmacytic differentiation in gastric mucosa-associated lymphoid tissue lymphomas: Helicobacter pylori eradication response and IgG4+ plasma cell association.
Park S; Ahn S; Hong M; Ko YH
Hum Pathol; 2017 Jan; 59():113-119. PubMed ID: 27697589
[TBL] [Abstract][Full Text] [Related]
9. t(11;18)(q21;q21)-positive advanced-stage MALT lymphoma associated with monoclonal gammopathy: resistance to rituximab or rituximab-containing chemotherapy.
Ohno H; Isoda K
J Clin Exp Hematop; 2008 Nov; 48(2):47-54. PubMed ID: 19039196
[TBL] [Abstract][Full Text] [Related]
10. Treatment of gastric marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue with rituximab, cyclophosphamide, vincristine and prednisone.
Aguiar-Bujanda D; Llorca-Mártinez I; Rivero-Vera JC; Blanco-Sánchez MJ; Jiménez-Gallego P; Mori-De Santiago M; Limeres-Gonzalez MA; Cabrera-Marrero JC; Hernández-Sosa M; Galván-Ruíz S; Hernández-Sarmiento S; Saura Grau S; Bohn-Sarmiento U
Hematol Oncol; 2014 Sep; 32(3):139-44. PubMed ID: 24123108
[TBL] [Abstract][Full Text] [Related]
11. Regression of pulmonary MALT lymphoma after treatment with rituximab.
Chong EA; Svoboda J; Cherian S; Andreadis C; Downs LH; Zhuang H; Alavi A; Tsai DE; Schuster SJ
Leuk Lymphoma; 2005 Sep; 46(9):1383-6. PubMed ID: 16109620
[TBL] [Abstract][Full Text] [Related]
12. 90Y-ibritumomab tiuxetan (Zevalin) in heavily pretreated patients with mucosa associated lymphoid tissue lymphoma.
Hoffmann M; Troch M; Eidherr H; Traub-Weidinger T; Jonak C; Muellauer L; Raderer M
Leuk Lymphoma; 2011 Jan; 52(1):42-5. PubMed ID: 21133720
[TBL] [Abstract][Full Text] [Related]
13. Marginal zone lymphoma of mucosa-associated lymphoid tissue with prominent plasma cell differentiation affecting the palatine tonsil: histopathological and immunohistochemical analysis.
Carlos Bregni R; Nuyens M; Vassallo J; Soares FA; Romañach MJ; León JE; Almeida OP
Oral Surg Oral Med Oral Pathol Oral Radiol; 2012 Apr; 113(4):526-32. PubMed ID: 22668431
[TBL] [Abstract][Full Text] [Related]
14. Second-line 90Yttrium-ibritumomab tiuxetan (Zevalin) in a patient with conjunctival mucosa-associated lymphoid tissue lymphoma refractory to rituximab.
Oellers P; Savar A; Samaniego F; Pro B; Esmaeli B
Ophthalmic Plast Reconstr Surg; 2012; 28(6):e145-6. PubMed ID: 22820440
[TBL] [Abstract][Full Text] [Related]
15. A retrospective analysis of primary gastric diffuse large B-cell lymphoma with or without concomitant mucosa-associated lymphoid tissue (MALT) lymphoma components.
Li X; Xia B; Guo S; Zhan Z; Zhang L; Zhao D; Wu X; Zhang Y
Ann Hematol; 2013 Jun; 92(6):807-15. PubMed ID: 23417758
[TBL] [Abstract][Full Text] [Related]
16. [Abnormal expression of bcl-10 protein in extranodal marginal zone B cell lymphoma of mucosa-associated lymphoid tissue lymphoma type].
Li BZ; Zhou XY; Ye HT; Yang WT; Fan YZ; Lu HF; Shi DR
Zhonghua Bing Li Xue Za Zhi; 2007 Dec; 36(12):819-24. PubMed ID: 18346354
[TBL] [Abstract][Full Text] [Related]
17. 18F-Fluoro-deoxy-glucose positron emission tomography in lymphoma of mucosa-associated lymphoid tissue: histology makes the difference.
Hoffmann M; Wöhrer S; Becherer A; Chott A; Streubel B; Kletter K; Raderer M
Ann Oncol; 2006 Dec; 17(12):1761-5. PubMed ID: 16980600
[TBL] [Abstract][Full Text] [Related]
18. Multifocal extranodal mucosa-associated lymphoid tissue lymphoma affecting the larynx.
Arndt S; Veelken H; Schmitt-Gräff A; Aschendorff A; Maier W; Richter B
Ann Otol Rhinol Laryngol; 2007 Apr; 116(4):257-61. PubMed ID: 17491523
[TBL] [Abstract][Full Text] [Related]
19. Can Interim 18F-FDG PET or Diffusion-Weighted MRI Predict End-of-Treatment Outcome in FDG-Avid MALT Lymphoma After Rituximab-Based Therapy?: A Preliminary Study in 15 Patients.
Mayerhoefer ME; Karanikas G; Kletter K; Kiesewetter B; Weber M; Rausch I; Pones M; Simonitsch-Klupp I; Müllauer L; Dolak W; Lukas J; Raderer M
Clin Nucl Med; 2016 Nov; 41(11):837-843. PubMed ID: 27648705
[TBL] [Abstract][Full Text] [Related]
20. Mucosa-associated lymphoid tissue lymphoma with unusual
Zhang NS; Shi F; Kong L; Zhu H
World J Gastroenterol; 2017 Jan; 23(3):551-559. PubMed ID: 28210093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
